Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan. The Overseas business comprises of sales and production in Europe, Taiwan and China. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

Tillotts is a leading international specialty pharmaceutical company with an established presence in Europe and in the rest of the world. Tillotts markets its own products such as Asacol™ and Entocort™ as well as in-licensed products in over 65 countries through its affiliates within Europe and a network of gastroenterology-focused partners throughout the world. Tillotts is part of the Japanese Zeria Group.

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998 and is headquartered in Copenhagen, Denmark.

Part of Zoetis, Inc., Zoetis Services LLC is a company headquartered in Florham Park, NJ, that discovers, develops, manufactures and sells animal health medicines and vaccines.

Part of AbbVie, Inc., AbbVie Biotherapeutics, Inc. is an American company located in North Chicago, IL, that develops oncology drugs.

Apexigen America, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology. Its product portfolio includes humanized antibodies, targeting diseases such as cancer, inflammatory diseases and ophthalmic disease. The company was founded by Xiao Dong Yang in July 2010 and is headquartered in San Carlos, CA.

Nanjing Wei Chuan Internet of Things Technology Co., Ltd., established on 2015-05-29, Business scope includes computer,Biotechnology Technology Development,technical consulting,Technical Services,technology transfer;business inquiries;computer software development;computer system integration;sensor,Instrumentation,Machinery & Electronics,electronic communication equipment,biological reagent,Chemical Products,Sales of laboratory equipment and appliances;biomedical technology development.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Chong Kun Dang Pharmaceutical Corp. engages in the manufacture, distribution, research, and development of pharmaceuticals. Its products include medicine for antidiabetic, antivirus, beta-blocking, anti-hyperlipidemia and others. The company was founded on November 5, 2013 and is headquartered in Seoul, South Korea.

Founded in 1998 as a spin out of the University of Zurich, ESBATech is committed to becoming one of the leading developers of fully human antibody fragments for therapeutic applications. The company applies its proprietary, fully human single-chain antibody frameworks to generate product candidates against targets of clinical relevance. ESBATech is focused on delivering high concentrations of its therapeutic antibody fragments to the targeted sites, in combination with extremely low systemic load, in order to achieve low risk of systemic drug reactions using topical and local delivery.

AvidBiotics is a biotherapeutics company deploying a proprietary biotechnology-derived technology platform that has multiple applications in life sciences. The company develops novel, non-antibody proteins used to target bacteria, virus-infected cells, and cancers. Its portfolio of therapeutic protein candidates and protein engineering platforms specifically flags virus-infected or cancerous cells for enhanced destruction by the Natural Killer and T-cells of the potent innate immunity systems and focuses on human therapeutic applications of its technologies that enable physicians to activate the immune system to target and destroy cancer cells infected by viruses with laser precision.

Cell IDx is the technology leader in multiplexed cellular immunodiagnostics. It serves as a privately held biotechnology company committed to developing highly sensitive and specific reagents for research and clinical immunohistochemistry. It was founded in 2013 and headquartered in San Diego, California.

Research Development Foundation is an American private company that operates as noncommercial research organizations.

Xyphos Biosciences, Inc. engages in biotechnology business. The firm’s novel and proprietary ACCEL (Advanced Cellular Control through Engineered Ligands) technology platform allows new ways to mobilize and control immune cells to find and destroy specifically targeted cells throughout the body. The company was founded by David W. Martin, Jr. and James L. Knighton and is headquartered in South San Francisco, CA.

National Research Council of Canada, provides research & development. It services include research programs and collaboration opportunities, technical and advisory services, licensing opportunities and industrial research assistance program. The company was founded by Graham W. Burton and is headquartered in Ottawa, ON.

Imperial Innovations is a technology commercialization and venture capital investor that focuses on technology. Imperial Innovations no longer invests in startups and now functions as the technology-transfer office of Imperial College. Imperial Innovations is focused on commercialising leading UK academic research sourced from the 'golden triangle' formed between Cambridge, Oxford and London. We are a technology commercialisation company that combines the activities of technology transfer, intellectual property protection and licensing, company incubation and investment. Innovations is focused on commercialising the most promising UK academic research across a broad range of technology sectors, and has developed particular expertise in: therapeutics, medtech, engineering and materials and information communication technology.

Part of GSK Plc, GlaxoSmithKline Intellectual Property Development Ltd. is a British company located in Middlesex that functions as an investment holding company. It was founded in 2012.\nThe company says this about itself: The Company is a member of the GlaxoSmithKline Group (the \"Group\"). The Company's principal activities are the development, enhancement, maintenance, protection and exploitation of intellectual property assets owned by the Company which may include but are not limited to, licensing out intellectual property rights relating to pharmaceutical products to the GlaxoSmithKline Group of companies (the \"Group\") and carrying out research and development activities.